The Central Drugs Standard Organisation (CDSO) has approved the shelf life of COVID-19 vaccines Covaxin to 12 months, Covishield to nine months, and ZyCoV-D to six months from the date of manufacture, the Lok Sabha was informed on Friday.
According to Immunization Officer Dr Tarun Gupta, they are running vaccination drives at 290 centers across the district and people can take the first and second dose of both Covishield and Covaxin.
Several facilities said with the ₹150 service charge fixed by the PM in June 7 address, it may not be viable to conduct immunisation on a massive scale.
URL copied
Covishield produces more antibodies with higher seropositivity rate than Covaxin
A preliminary study by Coronavirus Vaccine-induced Antibody Titre (COVAT) has stated Covishield vaccine produced more antibodies than Covaxin. The study, involving healthcare workers (HCW) who have received both doses of either of the two vaccines, also said seropositivity rates to anti-spike antibody were significantly higher in Covishield recipients as compared to Covaxin after the first dose.
The study is a preprint and has not been peer-reviewed, so should not be used to guide clinical practice.
It said that both vaccines Covishield and Covaxin elicited a good response after two doses, but seropositivity rate and median anti-spike antibody were significantly higher in Covishield.